Patents by Inventor Daniela Eberts

Daniela Eberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MHC-independent tumor-associated antigens
    Patent number: 10987413
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 27, 2021
    Assignee: BioNTech RNA Pharmaceuticals GmbH
    Inventors: Dirk Schadendorf, Annette Paschen, Silke Lübcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
  • Novel MHC-Independent Tumor-Associated Antigens
    Publication number: 20180099033
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Application
    Filed: November 30, 2017
    Publication date: April 12, 2018
    Inventors: Dirk SCHADENDORF, Annette PASCHEN, Silke LÜBCKE, Martina FATHO, Daniela EBERTS, Hakim ECHCHANNAOUI, Volker LENNERZ, Catherine WOELFEL, Thomas WOELFEL
  • T cell receptors with MHC independent binding to GM-CSF receptor alpha chain
    Patent number: 9861688
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 9, 2018
    Assignees: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Universitaet Duisburg-Essen
    Inventors: Dirk Schadendorf, Annette Paschen, Silke Luebcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
  • Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof
    Publication number: 20150366957
    Abstract: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
    Type: Application
    Filed: July 7, 2015
    Publication date: December 24, 2015
    Inventors: Daniela EBERTS, Martina FATHO, Volker LENNERZ, Chris SCHMIDT, Pierre VAN DER BRUGGEN, Catherine WÖLFEL, Thomas WÖLFEL
  • Novel MHC-Independent Tumor-Associated Antigens
    Publication number: 20150313978
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 5, 2015
    Inventors: Dirk SCHADENDORF, Anette PASCHEN, Silke LUEBCKE, Martina FATHO, Daniela EBERTS, Hakim ECHCHANNAOUI, Volker LENNERZ, Catherine WOELFEL, Thomas WOELFEL
  • Melanoma-associated MHC class I associated oligopeptides and the uses thereof
    Publication number: 20090104186
    Abstract: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
    Type: Application
    Filed: August 31, 2006
    Publication date: April 23, 2009
    Inventors: Daniela Eberts, Martina Fatho, Volker Lennerz, Chris Schmidt, Pierre Van Der Bruggen, Catherine Wolfel, Thomas Wolfel